Open AccessIs Use of BMP-2 Associated with Tumor Growth and Osteoblastic Differentiation in Murine Models of Osteosarcoma?
Author(s) -
Joseph K. Kendal,
Arvind K. Singla,
A. Affan,
Kurt Hildebrand,
Abdullah Al-Ani,
Mark Ungrin,
Douglas J. Mahoney,
Doha Itani,
Frank R. Jirik,
Michael J. Monument
Publication year - 2020
Publication title -
clinical orthopaedics and related research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.178
H-Index - 204
eISSN - 1528-1132
pISSN - 0009-921X
DOI - 10.1097/corr.0000000000001422
Subject(s) - medicine , osteosarcoma , bone morphogenetic protein 2 , bone morphogenetic protein , cancer research , pathology , gene , genetics , in vitro , biology
The putative benefit of rhBMP-2 is in the setting of limb reconstruction using structural allografts, whether it be allograft-prosthetic composites, osteoarticular allografts, or intercalary segmental grafts. There are also potential advantages in augmenting osseointegration of uncemented endoprosthetics and in reducing infection. Recombinant human BMP-2 might mitigate nonunion in structural allograft augmented osteosarcoma limb salvage surgery; however, its use is limited because of concerns about the prooncogenic effects of the agent.